Description of Event or Problem · 1
SUBJECT WAS ENROLLED IN THE RHEUMATOID ARTHRITIS STUDY (A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE BLIND, "SHAM" PHERESIS-CONTROLLED, STUDY OF EXTRACORPOREAL PHOTOIMMUNE THERAPY (ECP) WITH UVADEX FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN PATIENTS WHO HAVE AN INADEQUATE RESPONSE TO DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND BIOLOGICAL AGENTS.) THE PATIENT HAD A MEDICAL HISTORY OF ANEMIA. SUBJECT RECEIVED ECP THERAPY FOR 38 DAYS. ON EVENT DATE SUBJECT EXPERIENCED A 250CC BLOOD LOSS DURING ECP THERAPY. OPERATOR NOTICED PLASMA LEAKING FROM BOWL, POSSIBLY FROM SEAL AREA, DURING CYCLE 1 BUFFY COLLECTION. AS A PRECAUTION, TREATMENT WAS DISCONTINUED AND BLOOD WAS NOT RETURNED TO THE PATIENT. NO BLOOD LEAK OR OTHER ALARMS OCCURRED. THE CENTRIFUGE BOWL, THE CELL SEPARATOR PORTION OF THE XT-125 PROCEDURAL KIT, WAS RETURNED TO THERAKOS FOR EVALUATION. A ONE HALF INCH CRACK WAS FOUND IN THE STEM OF THE UPPER BOWL ASSEMBLY HEADER SHIELD. THE BOWL WAS SANITIZED WITH 10% BLEACH SOLUTION AND SENT TO HARMONETICS CORPORATION, MANUFACTURER OF THE CENTRIFUGE BOWL. HAEMONETICS CONFIRMED THE BOWL LEAK.